Sumitomo Dainippon Pharma : Posted Presentation Material (Frontier Business Meeting - FBO Showcase -)

Frontier Business Meeting

- FBO Showcase -

Hiroshi Nomura Representative Director, President and CEO

Disclaimer Regarding Forward-looking Statements

This material contains forecasts, projections, targets, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties.

Accordingly, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.

This document was prepared to explain the nature of Frontier Business; it is not intended to endorse any specific product or to make a commercial profit. Information contained herein includes material on devices and solutions that are under development or being planned for development, but such content is not intended as advertising or medical advice. Nor is it to be construed as including recommendations for such devices or solutions.

2

Frontier Business Domain

In anticipation of environmental changes in the future, such as the spread of preventive medicine and digital technology, Frontier Business is launched with the aim of providing new solutions to address social issues in the healthcare area other than pharmaceuticals

Global Specialized Player

Pharmaceuticals＋Solutions	Global leader in 3 areas	Best in
			Psychiatry
Medicine / Cell		Healthcare	Oncology Regenerative	class
	Solution	&	focused
Therapy		(Frontier business)	Neurology	/ Cell	on value

in 2033

Aiming to establish Frontier Business as a growth engine in the medium to long term, following the group's pharmaceutical business

3

Establishment of Frontier Business Office: April, 2019

• Focusing on areas in which synergies can be expected with the group's pharmaceutical

business

Psychiatry	Motor	Lifestyle
&	-related	Oncology
Dysfunction
Neurology	disease

• Building a business foundation on, among others, core technologies (information, engineering, etc.) and networking (via alliances, investment in venture businesses, etc.)
• Initiating and developing multiple pilot solution projects, including the coordination of initiatives for prevention, prediction, cure, and care
• Exploring commercialization opportunities primarily in Japan, the U.S., and China

4

Future Vision for Frontier Business

Senior Executive Officer Hiroyuki Baba